HUE031266T2 - Agomelatin új kokristályai - Google Patents
Agomelatin új kokristályai Download PDFInfo
- Publication number
- HUE031266T2 HUE031266T2 HUE12171231A HUE12171231A HUE031266T2 HU E031266 T2 HUE031266 T2 HU E031266T2 HU E12171231 A HUE12171231 A HU E12171231A HU E12171231 A HUE12171231 A HU E12171231A HU E031266 T2 HUE031266 T2 HU E031266T2
- Authority
- HU
- Hungary
- Prior art keywords
- ssä
- dig dig
- alkalmas
- ski ski
- λύΐη
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims description 11
- 239000002253 acid Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 206010027599 migraine Diseases 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 3
- 241001093575 Alma Species 0.000 claims 1
- 208000019399 Colonic disease Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 241000238557 Decapoda Species 0.000 claims 1
- 101100365384 Mus musculus Eefsec gene Proteins 0.000 claims 1
- 241000750004 Nestor meridionalis Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 101100460204 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new4 gene Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 230000001627 detrimental effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001544 dysphoric effect Effects 0.000 claims 1
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940047135 glycate Drugs 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000001769 paralizing effect Effects 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 235000013522 vodka Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 12
- 238000010586 diagram Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 244000287680 Garcinia dulcis Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 241000931365 Ampelodesmos mauritanicus Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101100016398 Danio rerio hars gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000157653 Psora Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241001582326 Renia Species 0.000 description 1
- 241000271569 Rhea Species 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000020129 lassi Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (7)
- !, ÂéOÉà&Pi· -M%á$táW> Ädl jM&iaesvv, hagy akOsdikvs&kOai äli>·:Sä < agy sgarvss ;-av pSísOdd^xitxxaoasív. gäHovxsas, üSidoncüv. ghs?ik:;sv, gdkoBsv ésJíe&gkííáfssv k<··· Aif k;véia\síss.
- 2. ÄS L igeaygöai sssäoO kôkséÂâiÿj ássál jéU«megseí l'iegv §§. %0$$&$ß8 Mö|#áisí Sé* bcsségéí a 11. kiéÂà|S'fôfôÂI'é>S bs.v>«iiu·».
- 3. As \. vagy m>. jgéîiypons <.i:oïhi:î kaksàaâly, assit! JeMefSittVi·- hogy & kokmíáh- a hsaoariyag kdoléadS' ss syhdaségáögk: legalsók |;S%>os asédosalâslt sdég! sl6 a lt< kHslálySyííag klôldàdSs! sàdàssdgével dssKàdasâHlkgéi semjsgys {gii6Ä) ν$$γ·$ßi K Ä^ÄkOOliaidayak kakOlt 4. äs 1 -I,. ig4ïwg-i)igdk k8fd>3ÄÄeAÄ®?Ä{kköksisi4iyj aa^alÿ hiiâKî\îbt'riï«esav gl/l), as s» s gdk'Kîsavg, hog> röfAgsapat siÄrskdfti kdvéîsls B s s y g 3 îhdta vxögakhiía ic-çg-sdvs ,f^2tb«n Moskva! 14,144 Wßi% %P\ ïf>9$% 35004°, 35565°, i$M% 20,25°, .23,494 35.003
- 4 . Ää I *$-. äglfiypoaiök: hárdislylkd sMdod kökyfsíáigj asddly Â^|3-Ç4:'Oî«fôkBl -néÀyÂéd(|iaî«aïftdà4>aî:S'· hidfaSihsnkodasv (132), dsgaUBlsgsssSs,. hagy römgagpai· diiMkciês ídtvé!«!« Brsgg 2 Oä!» %À^jk§&$tst»ÿr imp, 14,004 14204 1414-, 10,024 17,504 uus4 14,464041:,00421,344 22.004 22,974 22,554 22,264 24.444 25,054 26.624 28,424 22,7!4 29,8$° 6;.Az 43, IglfgysoikOk OOnOsMks sssHsh kakmíály, amdly gmkkgsHasxsas ( ! 623- akasl : jyiiaiia 629% Oogy rOOtgaspor I' 18114 sgogykOap : msgsÄ' Va (¾ J-Mn fe!ft|«IA63 14,474 !?Jl4 19J34 22J34 23,934
- 7, Äs 4-4 îgénÿpoOtôk Oargsglylka sssndh kpkylsdUy, aO'gly Ä4f2Ä^9iÄ08i-! -gafiOkeOlÎMsa SïOld/dOOsRssv 6!/! igàSxsi jë!3«gi&ây«,Â6gy mdigeppör OOfréfeclgs fplvéps!« BfSgg 2 tliîds ssOgakpsa msggadvs 440,2-b<:n 10,054 22,524 24.504 25,054 25,244 27,384 27.«r, 8, A.2 5-3, IgàhygspgÉ Oposélytkô asdApli kpkkiádÓy, aoiyly 59|2,(7-m4S68s-l-SäÄ43^4l!liä09O Áaild/gloíáva^ (171.4 akgailsllksssava, igigy Oiiiéia saógskOao magdOva (%0,2-hsn käfk|«k7J54 10,5?'-, 13,964 29.524 21,054 24 34 " %.A% Ι-J:. I§2n>ga5a2sk Mïinalÿikb syèmïli k$k?$$ál& amaly íV~ÍS-C?"ïîs§tí?:S|^ I"sísíÍIíÖ>-<í1sl|spé?v anslblgííksísav gl/% aæ*akjalî»mm% kâjgy IMvglgig Biggg 3 tbgla ssggakbkg k3Ss3va ( VCU-bas kibgsxva; 2)222 14..-12 Í-1.232 I7SP2 1JJ32 193 P. 20312 23322 243*2 >6.44'% 2232 22332 SCI, Âx: :!*|; íggbyi^öígk b;lxbialÿike SXgHöfl kiskrss^^i ·«?.#%" 33Í2.->(7b:8«tei''l'íía23:kskk|ss«í·-gbxkkke2sgkkS3i3 (Ι/f),. xíkkM Igllemegvss iasgy fdnigsxigox dlfekabk iblvktels Ersgg 2 tóa ssbgakbs« msgadva (23.2-3¾ klisjxxve} 15.332 12342 1634«, 53342 3332'2 23302:24312 ! | .lEflsnss §2 I ^IÖ. IgénjpönSök kokrissâlÿ: elSíkllMsárs, sms! Jeíkrom·*, &»ρ· a M2 alksklsax®!: össsb&svs};|:bk agy aws «Mbsxaibass sí k-fv&rt axáayakban: (1 .«ΙτνΜδ«»» ssgasbslsiM pas E3§ 3 sîîElskxlasfeiiS sï2ï· v:gs sakk - a kapna nklanss kavarjak3s aslog «selb®« · a -ktválasxteE skl6$a«r föwáapönrjánál »am magasabb bO--assasak 1» ïen ns« lagkjùk; - a kax-'as'bksî labinjuk* ka varaik 2s á kbknslály ísnnbyastas kinn klasagasllk: v«gy agy máSsdiknkkk sxsrbaa Isiváva kicsapódik: - a: ksjsop sMpdakis ÉMöEbfe ás mbgsgáBíjbk, 12. Í!jás2s aa l-fö. IpaygsssMk biinsslyiks saexlnű fcökPsnlly aiöáilkásarapnxasj |Änss*v% kagy a két ζΙκίΛύΐΗη ágyán «sisgbrnljisk.
- 13. Eháráa ax l-Hs. igésyporHök bámsdylke sxxirbai kakristály alöáliisásna, sxæal lallmam* hagy a kél Äö(is2sxt sxama vagy vixss^sxarvss 9ÍÉ»ta Â-æsk&ve^ilik 3s exxstásr-41)22 - -6<k'C tanamányfe» njegkí:gyasx|bík 2s !nsgsx:knp!.ik. 14 .: Eljárás sa I4Ö. Igsaygnaink Eännalylks sxssiaO kökíísíály «IMUMsáríg aææai jslíamnavp, hagy aa SgbaspiSlni as sí káíxiásbs sav ps2c agy k4vs3b«sí.3sSXsksS4gük:. ás giastáss & kevasakaä ikesmgás iVóscmjto-islssaí síglöljük sanglé sxaxsxXba ηΟΙίρΙΙ, így saikká gsninsláll laínsákas kajssmk .fcöa vaílanöl a sssjsalP kinsansláaáí.11, EÿégysxgMéaxkméagï ««ly balösísgagkésa agy* §& 14Ö. ígéaygnmnk bisxsalyílís smink kökílsssiy íagalasag. agy vagy sdbb gyógyssssásasöísg «llngsdisaP nsvil avas laxikas beráaséval kassbbEelM ban. 1 S: A15. Iglnypöäst sasrlaïi lE^gks^f'bksalnnëassa îablçilÎiaàieî-g ignibäsx xassdbllassasakgassägk kbzsilsb^ ív alkalmas gyágysxar »ÍMHltásáte-t^ébü-aikalmaAra;. 12. 4. IS. Iggayp-aaksaarbsli gyégysxgfMsallösbay sirassa, alvM'-re«à«lla»ass%2kÿ samopgkos rendéi« Isnassbgek: gs kilbnisan as skalkaiss sxnîxasgkskxansiellxnasség, :k®aysxæix;s-rôgasais2s ?and«Hmsasâga2 baa-gsslslbaliraîsslallaaassàgak: 2s kalsksbssa blpskaxls iangallanssskgsfc, msgï? gapsnssalb. .smzmUk aOakuvkas rsmlslksasség, szfv*#reÄä»lT kérss «Jvikßsssßlc, seaásáBlreobsserí káros- «Mltoxlsolg klösáím élíglláás kóvstkszíáfem jete^erJ· áhtmlsoság Is ftsdlkosyslg, skkoftéala* pá&ikráfcómölí* »tékákéiig. ##ggpd kgposdsMs eslsi resdslbsesslpk, altózásj ÂÂosâg* -íljstóomj psskkoölvis re«dédebb«ségeld egi|epgda4 o«köTka|>-ft^kwsoa ftsísgségí sggfcem siotebsl, sorssá! is és káros-áréjgeáéssel- kalses^s^.kálásbá'^^m^il?·“ nesslgöl, migrén, .ïiî«sa-èriav®82iéss Alzksimer kgtaSP^.&vllsbá á^-ksrfegásl .sIsklsJisosssIgM; Is sgegdábs működlss zRvsrok kesîBilsIb««, bsvábbl pgte&fe MhsÖíti»^éá|· -és: :tejäÄü«MbMÄbkk^lti. vgigmmt: táksök kbáeláslbso alkgtBi&ehsíé gylgyseerok glőálMíásárg lörisná : áikaléyMsf s.
- 19. ΛK i-Kk igénypontok bársneMké saermíi koknsUViy mdatoronerg rendseer rendeilensssIgshKk ke> xdéséte. l-9> Sla i*iö. |g^>fságíák ;blÁá$9$l§ S2«fiöíkköksisíá!yök suyssíy idysstr^dllfeskss%B.ks sybiangksos: raiBtensnssségek es különöset: ás általános sxorongàsi rendellenesség, kénysKetes-fögesKOés í<anitdlc»ességok. bgbgÄifesli syüdd|i®sgss|gek # kiddoösen bipoláris irébdsllénésségekj ssgjpf dspíysgság sxasöntíis sf&MvMS: iysdgllsnlsslg, sgly-^rgiyisylngkMM elyáisöxiábks: B?BlS2t|{'«»dsä®ri Mrd* elyáitbeásók, idláMs. sltöiádás ká¥#íiöllál?k| j|j|atkeg§ álnmllensslg Is %sd|kbôÿsà|... ski:ætV|bi% ji|Bikrdb|inbk; át¥MigVáI k|pdsi>ältiss evlsi reHdeiÍ#gssigsks «itdgátg #H!â|!aàsâg( tifdgktsrg'í^|ö!|01[I;|9# ..?9Ρ4^0#δ·^§^Ι» sj$gjjfs$&. önkorba;, Parkinson betegség, aggkori ehnebat. normális es kóros öregedéssel kapcsolatos kolöobörö rendellenességek, migrén. nnernornivesrréi, Alsdtelrner betegség, továbbá agyi keringési rendellenességek és sseruáUs ndködés; lísvarok kezelésében. továbbá peteérés inhibitorokkétu és nnnmrnnednldtorokksin'. vakomat rákok keksilslbéd sdkgkbáidlidd ggoggsgsiflk élőáliitásákg: iörténi allitdtriazlsr Ik
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1101766A FR2976284B1 (fr) | 2011-06-09 | 2011-06-09 | Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CN201110245039 | 2011-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE031266T2 true HUE031266T2 (hu) | 2017-06-28 |
Family
ID=46178495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12171231A HUE031266T2 (hu) | 2011-06-09 | 2012-06-08 | Agomelatin új kokristályai |
Country Status (44)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2517700B1 (en) * | 2011-04-28 | 2013-07-17 | Zentiva, k.s. | Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation |
| ES2590908T3 (es) | 2012-12-17 | 2016-11-24 | Dr. Reddy's Laboratories Ltd. | Cocristal de agomelatina con ácido fosfórico |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| PL2810656T3 (pl) * | 2013-06-06 | 2018-01-31 | Zentiva Ks | Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów |
| WO2015013865A1 (en) * | 2013-07-29 | 2015-02-05 | Les Laboratoires Servier | Agomelatine sulfonic acids complexes and preparation thereof |
| ME03741B (me) * | 2013-07-29 | 2021-04-20 | Shanghai Inst Pharmaceutical Ind | Konpleksi agomelatina i sulfonskih kisjelina, postupak njihove proizvodnje i proizvodnje farmaceutskih pripravaka koji ih sadržavaju |
| CN105473551B (zh) * | 2013-07-31 | 2019-01-11 | 法国施维雅药厂 | 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物 |
| KR101404836B1 (ko) | 2014-03-21 | 2014-06-09 | 순천향대학교 산학협력단 | 아고멜라틴의 공결정 및 그의 제조방법 |
| KR101470794B1 (ko) * | 2014-06-30 | 2014-12-08 | 순천향대학교 산학협력단 | 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물 |
| EP3075724B1 (en) | 2015-03-31 | 2023-07-12 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
| KR101790411B1 (ko) | 2015-09-25 | 2017-10-26 | 순천향대학교 산학협력단 | 균일한 입도분포를 가지는 아고멜라틴 공결정 분체의 제조방법 |
| WO2017115284A1 (en) * | 2015-12-28 | 2017-07-06 | Leiutis Pharmaceuticals Pvt, Ltd. | Novel co-crystal forms of agomelatine |
| FI3468944T3 (fi) * | 2016-06-13 | 2023-01-31 | Natriumbentsoaatin yhteiskiteitä ja niiden käyttöjä | |
| AU2017366192A1 (en) * | 2016-11-23 | 2019-06-06 | Bohne Askøy As | Prevention and/or treatment of chronic fatigue syndrome |
| EP3466413A1 (en) * | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
| US20240116932A1 (en) | 2022-09-07 | 2024-04-11 | Eli Lilly And Company | Cocrystalline forms of fgfr3 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| AU2004308962A1 (en) * | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
| FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
| WO2008035177A2 (en) * | 2006-09-18 | 2008-03-27 | Copharm | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor |
| FR2908995B1 (fr) * | 2006-11-24 | 2009-02-06 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis |
| FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| CN101870662B (zh) * | 2010-05-21 | 2013-03-20 | 中山大学 | 结晶型阿戈美拉汀溶剂化物及其制备方法 |
| WO2012046253A2 (en) * | 2010-10-08 | 2012-04-12 | Msn Laboratories Limited | Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms |
| CN102690210A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
| CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
| EP2517700B1 (en) | 2011-04-28 | 2013-07-17 | Zentiva, k.s. | Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation |
-
2012
- 2012-05-25 PH PH12012000132A patent/PH12012000132A1/en unknown
- 2012-05-28 JO JOP/2012/0132A patent/JO3213B1/ar active
- 2012-05-28 SG SG2012038949A patent/SG186548A1/en unknown
- 2012-05-28 TN TNP2012000266A patent/TN2012000266A1/fr unknown
- 2012-05-29 PE PE2012000732A patent/PE20130047A1/es not_active Application Discontinuation
- 2012-05-29 CR CR20120287A patent/CR20120287A/es unknown
- 2012-05-30 IL IL220066A patent/IL220066A0/en active IP Right Grant
- 2012-05-30 CA CA2778850A patent/CA2778850C/fr active Active
- 2012-05-30 AU AU2012203196A patent/AU2012203196C1/en not_active Ceased
- 2012-05-31 UY UY0001034111A patent/UY34111A/es not_active Application Discontinuation
- 2012-05-31 MY MYPI2012700327A patent/MY159816A/en unknown
- 2012-06-04 EC ECSP12011949 patent/ECSP12011949A/es unknown
- 2012-06-04 MA MA34936A patent/MA34498B1/fr unknown
- 2012-06-05 GE GEAP201212736A patent/GEP20156339B/en unknown
- 2012-06-06 SA SA112330595A patent/SA112330595B1/ar unknown
- 2012-06-06 SV SV2012004235A patent/SV2012004235A/es active IP Right Grant
- 2012-06-06 CO CO12095643A patent/CO6580196A1/es unknown
- 2012-06-07 MD MDA20120050A patent/MD4308C1/ro not_active IP Right Cessation
- 2012-06-07 CL CL2012001501A patent/CL2012001501A1/es unknown
- 2012-06-07 AR ARP120102011A patent/AR086849A1/es unknown
- 2012-06-07 ZA ZA2012/04184A patent/ZA201204184B/en unknown
- 2012-06-08 MX MX2012006577A patent/MX2012006577A/es active IP Right Grant
- 2012-06-08 JP JP2012130471A patent/JP5525011B2/ja not_active Expired - Fee Related
- 2012-06-08 ES ES12171231.9T patent/ES2608799T3/es active Active
- 2012-06-08 TW TW101120779A patent/TWI441803B/zh not_active IP Right Cessation
- 2012-06-08 DK DK12171231.9T patent/DK2532647T3/en active
- 2012-06-08 KR KR1020120061605A patent/KR20120138223A/ko not_active Application Discontinuation
- 2012-06-08 SI SI201230823A patent/SI2532647T1/sl unknown
- 2012-06-08 LT LTEP12171231.9T patent/LT2532647T/lt unknown
- 2012-06-08 RS RS20161060A patent/RS55406B1/sr unknown
- 2012-06-08 PT PT121712319T patent/PT2532647T/pt unknown
- 2012-06-08 EP EP12171231.9A patent/EP2532647B1/fr active Active
- 2012-06-08 WO PCT/FR2012/051291 patent/WO2012168665A1/fr active Application Filing
- 2012-06-08 NI NI201200101A patent/NI201200101A/es unknown
- 2012-06-08 RU RU2013158816/04A patent/RU2593749C2/ru active
- 2012-06-08 ME MEP-2016-295A patent/ME02574B/me unknown
- 2012-06-08 HU HUE12171231A patent/HUE031266T2/hu unknown
- 2012-06-08 GT GT201200188A patent/GT201200188A/es unknown
- 2012-06-08 PL PL12171231T patent/PL2532647T3/pl unknown
- 2012-06-08 BR BR102012013816-6A patent/BR102012013816B1/pt not_active IP Right Cessation
- 2012-06-08 US US13/492,095 patent/US8710101B2/en active Active
- 2012-06-09 EA EA201200728A patent/EA021386B1/ru unknown
-
2016
- 2016-12-06 HR HRP20161647TT patent/HRP20161647T1/hr unknown
- 2016-12-14 CY CY20161101298T patent/CY1118439T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE031266T2 (hu) | Agomelatin új kokristályai | |
| Tominaga et al. | Capsaicin receptor in the pain pathway | |
| Kniazeff et al. | Dimers and beyond: The functional puzzles of class C GPCRs | |
| Picci et al. | HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice | |
| Mueller-Tribbensee et al. | Differential contribution of TRPA1, TRPV4 and TRPM8 to colonic nociception in mice | |
| WO2013120040A1 (en) | Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy | |
| Alayoubi et al. | Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics | |
| Tiwari et al. | Rat palatability study for taste assessment of caffeine citrate formulation prepared via hot-melt extrusion technology | |
| Fox et al. | An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice | |
| Schwaller et al. | The developmental emergence of differential brainstem serotonergic control of the sensory spinal cord | |
| Ding et al. | Alterations of striatal neurotransmitter release in aquaporin-4 deficient mice: An in vivo microdialysis study | |
| Mantas et al. | TAAR1-dependent and-independent actions of tyramine in interaction with glutamate underlie central Effects of monoamine oxidase inhibition | |
| B Hughes et al. | Ketamine restores thalamic-prefrontal cortex functional connectivity in a mouse model of neurodevelopmental disorder-associated 2p16. 3 deletion | |
| Delport et al. | Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties | |
| Dick et al. | NMDA receptor binding is reduced within mesocorticolimbic regions following chronic inhalation of toluene in adolescent rats | |
| US10849878B2 (en) | Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon | |
| Yang et al. | Effects of benzo (a) pyrene exposure on the ATPase activity and calcium concentration in the hippocampus of neonatal rats | |
| Roelofs et al. | Isoflurane anesthetic hypersensitivity and progressive respiratory depression in a mouse model with isolated mitochondrial complex I deficiency | |
| KR102428383B1 (ko) | 중추신경계 및 혈관계에 대한 활성을 가진 벤조디아제핀 생성물 | |
| Ciarimboli | Introduction to the cellular transport of organic cations | |
| Xiang et al. | CREB down-regulation in the laterodorsal thalamic nucleus deteriorates memory consolidation in rats | |
| Wang et al. | Wolfram syndrome 1b mutation suppresses Mauthner-cell axon regeneration via ER stress signal pathway | |
| Kožárová et al. | High-performance liquid chromatographic determination of sulfadimidine residues in eggs | |
| Yuan et al. | A multi-dosing regimen to enhance the spatial memory of normal rats with α5-containing GABA A receptor negative allosteric modulator L-655,708 | |
| JP2016204303A (ja) | 抗健忘症用組成物 |